{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:53:52Z","timestamp":1790222032096,"version":"4.1.0"},"reference-count":22,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":891,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1111\/ijcp.12065","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T10:07:31Z","timestamp":1364551651000},"page":"333-341","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction"],"prefix":"10.1155","volume":"67","author":[{"given":"L. H.","family":"Belkoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"DiDonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Trask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2013,3,24]]},"reference":[{"key":"10.1111\/ijcp.12065-BIB1|cit1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjmed.2006.06.010","article-title":"Prevalence and risk factors for erectile dysfunction in the US","volume":"120","author":"Selvin","year":"2007","journal-title":"Am J Med"},{"key":"10.1111\/ijcp.12065-BIB2|cit2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"10.1111\/ijcp.12065-BIB3|cit3","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-5347(05)67900-1","article-title":"Incidence of erectile dysfunction in men 40-69\u2003years old: longitudinal results from the Massachusetts male aging study","volume":"163","author":"Johannes","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1111\/ijcp.12065-BIB4|cit4","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/sj.ijir.3901205","article-title":"Mechanisms of action of PDE5 inhibition in erectile dysfunction","volume":"16","author":"Corbin","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1111\/ijcp.12065-BIB5|cit5","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1111\/j.1743-6109.2011.02473.x","article-title":"Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient","volume":"8","author":"Corona","year":"2011","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12065-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1743-6109.2010.01849.x","article-title":"Erectile dysfunction in the community: trends over time in incidence, prevalence, GP consultation and medication use - the Krimpen study: trends in ED","volume":"7","author":"Schouten","year":"2010","journal-title":"J Sex Med"},{"issue":"1 Pt 2","key":"10.1111\/ijcp.12065-BIB7|cit7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1743-6109.2009.01627.x","article-title":"Pharmacotherapy for erectile dysfunction","volume":"7","author":"Eardley","year":"2010","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12065-BIB8|cit8","volume-title":"Viagra (package insert)","author":"Pfizer Labs","year":"2010"},{"key":"10.1111\/ijcp.12065-BIB9|cit9","volume-title":"Cialis (package insert)","author":"Eli Lilly and Company","year":"2011"},{"key":"10.1111\/ijcp.12065-BIB10|cit10","volume-title":"Levitra (package insert)","author":"Bayer HealthCare Pharmaceuticals, Inc","year":"2011"},{"key":"10.1111\/ijcp.12065-BIB11|cit11","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ijir.3901208","article-title":"Potency, selectivity, and consequences of nonselectivity of PDE inhibition","volume":"16","author":"Bischoff","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1111\/ijcp.12065-BIB12|cit12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1742-1241.2009.02254.x","article-title":"Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database","volume":"64","author":"Giuliano","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12065-BIB13|cit13","volume-title":"STENDRA (package insert)","author":"VIVUS, Inc","year":"2012"},{"key":"10.1111\/ijcp.12065-BIB14|cit14","first-page":"S466","article-title":"Pharmacokinetics of avanafil, a novel, rapidly absorbed, selective PDE5 inhibitor for the treatment of mild to severe erectile dysfunction","volume":"8","author":"Allison","year":"2011","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12065-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1743-6109.2011.02629.x","article-title":"A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction","volume":"9","author":"Goldstein","year":"2012","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12065-BIB16|cit16","article-title":"A phase 2, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction","author":"Hellstrom","year":"2012","journal-title":"BJU Int"},{"key":"10.1111\/ijcp.12065-BIB17|cit17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.mayocp.2012.06.016","article-title":"Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes","volume":"87","author":"Goldstein","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/ijcp.12065-BIB18|cit18","first-page":"14","article-title":"Safety and efficacy of avanafil, a new PDE5 inhibitor for treating erectile dysfunction","volume":"3","author":"Kaufman","year":"2006","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12065-BIB19|cit19","first-page":"S42","article-title":"A phase III, placebo-controlled study of the safety and efficacy of avanafil in the treatment of erectile dysfunction following bilateral, nerve-sparing radical prostatectomy","volume":"9","author":"Mulhall","year":"2012","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12065-BIB20|cit20","unstructured":"Mulhall JP Burnett AL McVary KT Efficacy and safety of avanafil, a next-generation, phosphodiesterase type 5 inhibitor for the treatment of men with erectile dysfunction: data from phase 2 and 3 studies in difficult-to-treat populations"},{"key":"10.1111\/ijcp.12065-BIB21|cit21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"10.1111\/ijcp.12065-BIB22|cit22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.juro.2012.03.115","article-title":"Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction","volume":"188","author":"Kotera","year":"2012","journal-title":"J Urol"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12065","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:06:36Z","timestamp":1643349996000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12065"}},"subtitle":["Long-term safety, efficacy and tolerability of avanafil for erectile dysfunction"],"short-title":[],"issued":{"date-parts":[[2013,3,24]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12065","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3,24]]},"assertion":[{"value":"2013-03-24","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}